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Introduction
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a CNS inflammatory disorder characterized by pontine predominant, punctate, gadolinium enhancing MRI lesions with exquisite response to corticosteroid therapy (Pittock et al., 2010) . CLIPPERS has characteristic clinical, radiological and pathological findings, but the lack of formalized diagnostic criteria and definitive biomarkers results in diagnostic uncertainty. Retrospective evaluation of previously unclassified neurological diseases identified patients with CLIPPERS in several practice settings (Taieb et al., 2012; Kerrn-Jespersen et al., 2014) . Follow-up for a mean of 5.5 years demonstrated no alternative diagnosis among 12 patients with CLIPPERS (Taieb et al., 2012) . Alternative diagnoses, such as primary CNS malignancy, found in patients initially suspected to have CLIPPERS (Jones et al., 2011; Limousin et al., 2012; De Graaff et al., 2013; Lin et al., 2014; Taieb et al., 2014) led some authors to advocate for neuropathological evaluation in all suspected cases (Limousin et al., 2012) . The occurrence of suspected CLIPPERS associated with systemic T cell lymphoma (Nakamura et al., 2016 ), Hodgkin's lymphoma (Mashima et al., 2015) , chronic hepatitis B infection (Weng et al., 2015) , myelin oligodendrocyte glycoprotein (MOG) antibodies (Symmonds et al., 2015) , CNS lymphomatoid granulomatosis (Wang et al., 2017) , primary cerebral angiitis (Buttmann et al., 2013) and multiple sclerosis (Ortega et al., 2012; Ferreira et al., 2013) , further demonstrates the need for diagnostic clarity. We performed a comprehensive clinical, radiological and pathological evaluation of 35 patients reviewed at Mayo Clinic with a suspected diagnosis of CLIPPERS and propose diagnostic criteria for CLIPPERS.
Materials and methods

Patients
This study was approved by the Mayo Foundation Institutional Review Board (IRB#14-003720). All patients consented to the use of their medical records for research purposes at the time of their clinical evaluation at Mayo Clinic. Followup data from five patients included in the authors' previous publication on CLIPPERS were also included (Cases 6, 7, 11, 20 and 21) .
Clinical, radiological and pathological data were collected from patients whose treating neurologist had made a presumptive diagnosis of CLIPPERS. Retrospective identification of cases was performed by review of pathology and neuroradiology records at Mayo Clinic, Rochester between 1996 and 2009. All patients referred for review at Mayo Clinic, Rochester with suspected CLIPPERS through a tertiary subspeciality clinic, physician referral and by self-identification through partnership with a patient advocacy website (livingwithclippers.blogspot.com) were included from January 2010 to December 2016. Clinical outcome was determined by inperson evaluation, telephone interview and/or medical record review. Disability was assessed using the modified Rankin scale (van Swieten et al., 1988) .
Clinical and radiological data were reviewed by three neurologists (W.O.T., S.J.P., B.M.K.) to confirm the diagnosis of CLIPPERS by consensus agreement based on consistent interpretation of clinical, and radiological features. Clinical and radiological features of CLIPPERS were: (i) subacute progressive pontocerebellar dysfunction; (ii) bilateral punctate enhancing lesions on MRI brain, predominantly in the pons or cerebellum; (iii) absence of lesion-associated mass effect; (iv) radiographic reduction in the number and size of enhancing lesions following corticosteroid treatment typically with substantial clinical improvement; and (v) no better explanation for clinical and radiographic findings.
Imaging
Neuroimaging was independently evaluated by an experienced neuroradiologist (K.N.K.) blinded to the consensus clinical diagnosis of the neurologists. Brain MRI was performed in 1.5 T and 3.0 T MRI scanners, and images from T 1 (preand post-administration of gadolinium), T 2 , fluid attenuation inversion recovery (FLAIR) and proton density sequences were acquired. A median of six brain MRIs (range 2-14) per patient were available for review, spanning a median interval of 18 months (range 1-183 months) and including pre-and posttherapy images. Spinal cord MRI was available for 24 patients and were performed on 1.5 and 3 T scanners with standard imaging sequences of T 1 and T 2 sagittal plane, axial T 2 and gradient-echo in the axial plane and post-gadolinium administration T 1 sagittal plane and frequently in the axial plane.
Intracranial vascular imaging was available in seven patients with CLIPPERS [magnetic resonance angiogram (n = 6), CT angiogram (n = 1), catheter angiogram (n = 1)]. Non-CLIPPERS patients had intracranial vascular imaging in four cases [magnetic resonance angiogram (n = 3), CT angiogram (n = 1)].
Chest CT imaging was available in 18 patients and abdominal and pelvic CT in 14 patients. Brain 18 F-fluorodeoxyglucose (FDG)-PET was performed in seven CLIPPERS patients with body FDG-PET in 11 CLIPPERS patients. Non-CLIPPERS patients had brain FDG-PET in four cases and body FDG-PET in six cases.
Pathology
Brain pathological tissue on 19 patients (18 biopsy cases; one with both biopsy and autopsy) was examined by three independent neuropathology experts (Y.G., C.F.L., J.E.P.) blinded to the final clinical diagnosis. Five micrometre formalin-fixed paraffin embedded (FFPE) tissue sections were stained with haematoxylin and eosin, Luxol fast blue and periodic acidSchiff (LFB-PAS), and Bielschowsky silver impregnation for routine neuropathological assessment. Immunohistochemistry was performed with an avidin-biotin technique for myelin proteolipid protein (PLP) (1:500, Serotec), glial fibrillary acidic protein (GFAP) (1:100, Dako), CD68 (1:200, Dako), CD3 (1:200, Serotec), CD4 (1:120, Abcam), CD8 (1:50, Dako), CD20 (1:100 Dako), and CD138 (1:50, Dako), and neurofilament (1:800, Dako).
Autoimmune serological evaluation
Serum (n = 33) and CSF (n = 11) was available for neural autoantibody testing. We performed standardized indirect immunofluorescence assays for IgG antibodies: amphiphysin, antineuronal nuclear (ANNA)-1 (anti-Hu), ANNA-2 (anti-Ri), ANNA-3, collapsin response-mediator protein (CRMP)-5, antiglial/neuronal nuclear (AGNA)-1, Purkinje-cell cytoplasmic (PCA-1) (anti Yo), PCA-2, and PCA-Tr, glial fibrillary acidic protein (GFAP), N-methyl-D-aspartate (NMDA) receptor, -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, dipeptidyl-peptidase-like protein-6 (DPPX), metabotropic glutamate receptor (mGluR)-1, gamma-aminobutyric acid (GABA) B receptor, and GABA A receptor. Immunofluorescence assays were also used for detection of novel or unclassified neural-specific autoantibodies. Radioimmunoprecipitation assays were performed for antibodies targeting neuronal type voltage gated potassium channel complex (VGKC), P/Q type voltage gated calcium channel (VGCC), N-type VGCC, muscle (1) nicotinic acetylcholine receptor, and neuronal ganglionic (3) acetylcholine receptor, and glutamic acid decarboxylase-65 isoform (GAD65). Cell-based assays using HEK293 cells transfected with appropriate expression plasmids to detect antibodies targeting NMDA receptor, AMPA receptor, GABA receptors and GFAP-(Euroimmun, or in-house developed) were performed. For all VGKCc IgG positive specimens, cell-based assays for leucine rich glioma inactivated 1 (LGI1) and contactin associated protein 2 (CASPR2) IgG using transfected HEK293 cells were performed (Euroimmun). Those yielding immunofluorescence assay patterns consistent with DPPX, mGluR1 and mGluR5 were confirmed by cell-based assays on transfected cell lines (Euroimmun). Aquaporin 4 (AQP4) and MOG IgG antibodies were detected by live in-house flow cytometry [fluorescence-activated cell sorting (FACS)]. Some AQP4 serum and CSF samples were also analysed by fixed AQP4 cellbased assay (Euroimmun).
Statistical analyses
Descriptive summaries were reported as median (range) for continuous variables and frequencies and percentages for categorical variables. CLIPPERS diagnosis by consensus agreement was used as a gold standard to classify patients as CLIPPERS (Yes/No) . Associations between clinical, neuroimaging and neuropathological variables were assessed using Fisher's exact test. Radiological features coded by an independent radiologist, blinded to the consensus diagnosis were evaluated for their predictive ability at diagnosing CLIPPERS. False discovery rate (FDR) correction approach was used to correct for multiple comparisons. All tests were two sided and P-values 5 0.05 were considered statistically significant. Analysis was performed using SAS software version 9.3 (SAS Inc., Cary, NC).
Results
Clinical characteristics
Twenty-three of 35 patients were diagnosed as having CLIPPERS by neurologists' consensus agreement. The clinical characteristics of patients with CLIPPERS are shown in Table 1 and compared with non-CLIPPERS in Table 2 . Non-CLIPPERS cases did not differ in clinical presentation or history of cancer (Table 2) .
Five CLIPPERS patients had known cancer prior to their neurological symptoms: malignant schwannoma (Case 3), breast cancer (Case 4), Epstein Barr virus-positive diffuse large B cell lymphoma (Case 5), prostate cancer (Case 9), and adrenal adenoma (Case 16). All cancers, apart from the diffuse large B cell lymphoma, were considered cured or inactive at the time of onset of neurological symptoms.
Two CLIPPERS patients developed cancer following their CLIPPERS diagnosis: one patient (Case 12) developed CNS lymphoma 33 months following onset of CLIPPERS symptoms, and 16 months following commencement of chronic CLIPPERS treatment with azathioprine. Another patient (Case 16) suffered splenic rupture requiring splenectomy during resection of an adrenal adenoma, and a low grade B cell lymphoma was incidentally found.
Following consensus review, 12 patients had a non-CLIPPERS diagnosis. An alternate diagnosis was reached in four patients: familial haemophagocytic lymphohistiocytosis, brainstem encephalitis following varicella zoster virus reactivation, multiple systems atrophy and primary CNS vasculitis. Of the remaining eight patients, four underwent brain biopsies without a confirmatory diagnosis.
Neuroimaging
All CLIPPERS patients had the characteristic MRI pattern of pontine and cerebellar punctate perivascular gadolinium enhancement that extended variably beyond that location, with 14/23 having CNS lesions outside the pontocerebellar and in spinal cord regions. Characteristic small punctate gadolinium enhancing CLIPPERS lesions involved: midbrain (n = 21), medulla (n = 16), subcortical white matter (n = 16), and cerebral hemispheres (n = 6). Differences in brain MRI characteristics between CLIPPERS and non-CLIPPERS patients are demonstrated in Figs 1 and 2 and compared in Table 3 . Corticosteroid therapy was typically associated with marked to complete resolution of post gadolinium T 1 contrast enhancement (Fig. 2) . All but one patient with CLIPPERS had a complete absence of enhancement following steroid treatment. In contrast, 10 patients with non-CLIPPERS had residual enhancement following treatment with steroids. Minor diffusion-weighted imaging (DWI) high signal was seen in one patient with CLIPPERS (Case 22) out of 22 patients with DWI MRI available. DWI high signal was seen in 4/11 patients with non-CLIPPERS.
Punctate gadolinium enhancing spinal cord lesions, with corresponding T 2 lesions were present in 10/17 of CLIPPERS patients and 1/7 non-CLIPPERS patient with spinal cord imaging available. No non-enhancing T 2 spinal lesions were seen in patients with CLIPPERS. Nonenhancing T 2 spinal lesions were seen in two additional non-CLIPPERS.
There was no radiological evidence of vasculitis or intravascular lymphoma among the CLIPPER cases evaluated with intracranial magnetic resonance angiogram (n = 6), CT angiogram (n = 1) and catheter angiogram (n = 1). Brain FDG-PET was performed in seven CLIPPERS patients and four non-CLIPPERS patients. FDG-PET hypermetabolism was demonstrated in the regions of T 1 post Diagnostic criteria for CLIPPERS gadolinium enhancement on brain MRI in one of seven CLIPPERS patients and two of four non-CLIPPERS patients. Diffuse FDG-PET cerebral hypometabolism was found in three CLIPPERS patients and one non-CLIPPERS patient.
Systemic imaging
CT chest was performed in 21 CLIPPERS patients and CT abdomen and pelvis in 15 patients. Adrenal adenoma was found in Case 16 with low grade B cell splenic lymphoma subsequently diagnosed. Splenomegaly and pulmonary nodules were found in Case 17 with a T cell infiltrate seen on splenic pathology without cancer diagnosis for over 8 years follow-up. Body FDG-PET was performed in 11 CLIPPERS patients and six non-CLIPPERS patients and showed hypermetabolism in one CLIPPERS patient (Case 5) with known systemic B cell lymphoma.
Neuropathology
Among the 19 patients reviewed pathologically, 14 were CLIPPERS and five non-CLIPPERS cases. For the CLIPPERS cases, white matter was available in 14, grey matter in 11 and meninges in three cases. All CLIPPERS cases demonstrated dense lymphocytic inflammation with perivascular predominance and parenchymal diffuse infiltration (Fig. 3) . In contrast, four of five non-CLIPPERS cases showed non-specific changes with no obvious inflammatory infiltration. Lymphocytic infiltration among the CLIPPERS cases involved both white (14/14) and grey matter (9/11), and meningeal inflammation was present in 3/3. Lymphocytic components were predominantly CD3-positive T-lymphocytes (13/13), with a smaller population of CD20-positive B-lymphocytes, usually accompanied by scattered mature-appearing plasma cells (11/14). CD4 cells predominated over CD8 cells. Neutrophils were present in 6/14 cases [perivascular (n = 2), diffuse parenchymal (n = 2), both (n = 2)] and eosinophils in 6/14 cases [perivascular (n = 1), diffuse parenchymal (n = 2), both (n = 3)]. Despite an intense inflammatory infiltrate among the CLIPPERS cases, there were no features of vasculitis (vessel wall splitting or prominent vascular lymphocytic infiltration). Prominent macrophage infiltration was present with round foamy or elongated branched morphology. Occasional areas of marked macrophage infiltration mimicked immature granuloma-like morphology; however, neither Langhans giant cells nor infectious agents were seen among the CLIPPERS cases. Variable tissue destruction was present ranging from mild (tissue vacuolization with mild microglia/macrophage reaction) to moderate (damaged and disorganized parenchymal cell components with enlarged intercellular space and obvious microglia/macrophage reactions). Reactive astrocytes were present, in the absence of Creutzfeldt-Peters cells. Non-confluent, ill-defined myelin loss was observed in 50% of the CLIPPERS cases, with relative axonal preservation (8/8 cases had few axonal spheroids).
One patient with genetically confirmed haemophagocytic lymphohistiocytosis showed similar pathology found in other CLIPPERS cases. Four of 19 patients did not have typical features supportive of CLIPPERS pathologically and were independently identified in a blinded fashion as non-CLIPPERS on clinical and radiographic grounds (Fig. 4) . Two cases had mild perivascular lymphocytes infiltration in the white matter with occasional scattered parenchymal infiltration. One case showed only non-specific gliosis. None of these patients had tissue destruction, granulocyte or plasma cell infiltration, or myelin loss.
Autoimmune serological evaluation
All samples (sera, n = 33; CSF, n = 11) tested were negative by immunofluorescence assays. None of the samples had neural-specific unclassified or potentially novel antibodies detected by immunofluorescence assay. Immunofluorescence assay patterns consistent with GFAP-/" IgG or AQP4 IgG were not detected in any of the patients. CLIPPERS serum samples (18 of 23) tested for GFAPIgG by cell-based assay were negative. All CLIPPERS and non-CLIPPERS samples tested for AQP4 by live-cell FACS or AQP4 transfected cell-based assay, were negative. MOG IgG by FACS was not detected in any CLIPPERS (20 of 23) and non-CLIPPERS (10 of 12) serum samples tested. Non-CLIPPERS patients had CSF abnormalities in 8/12 cases: mildly elevated protein in seven (50-1160 mg/dl; normal reference range 15-45 mg/dl) and pleocytosis in one (10 white blood cells ml/l). Abnormal elevations in unique CSF oligoclonal bands were found in one of nine tested. There were no statistically significant differences in CSF parameters between CLIPPERS and non-CLIPPERS patients (P 5 0.4).
Treatment and outcome
All patients with CLIPPERS and non-CLIPPERS aetiology were treated initially with either intravenous methylprednisolone (1 g daily for 5 days) or oral prednisone [range 20-60 mg daily (unclear duration in some patients)]. In the CLIPPERS group, the median time from symptom onset to corticosteroid treatment initiation was 197 days (range 1-5768 days). In the non-CLIPPERS group, median time from symptom onset to corticosteroid treatment initiation was 44.5 days (range 0-1003 days). All CLIPPERS patients had both clinical improvement and radiological improvement with the number and size of perivascular gadolinium enhancing lesions reduced on post-treatment MRI exams in all 23 patients and completely resolved in 10 patients (Fig. 2) . Non-CLIPPERS patients showed clinical improvement to treatment in 8/12 patients, and both clinical improvement and resolution of gadolinium enhancing lesions on MRI in 2/12 patients. The maximum reduction in modified Rankin score following treatment with corticosteroids was significantly more for the CLIPPERS group (modified Rankin score 3 to 1), than in the non-CLIPPERS group (modified Rankin score 3 to 2.5, P = 0.001). CLIPPERS patients were followed for a median of 44 months (range 11-219) following symptom onset. Median modified Rankin score at follow-up was 1. Eleven patients had steroid treatment withdrawn following initial therapy and all had a clinical worsening following steroid discontinuation. Three other CLIPPERS patients had clinical worsening during a steroid wean. This corresponded to a radiological relapse in all seven patients for whom images were available at the time of relapse. Seventeen patients were on chronic immunosuppressive medications: chronic oral steroids alone (prednisone 40-60 mg) (n = 5), steroids (prednisone 15-60 mg or regular intravenous methylprednisone) and concomitant steroid sparing agent [n = 4, methotrexate (n = 2), mycophenolate (n = 2)]. Steroid sparing immunosuppressive monotherapy: methotrexate (n = 3), azathioprine (n = 1), hydroxychloroquine (n = 1), rituximab (n = 1), cyclophosphamide (n = 1) and mycophenolate (n = 1). One patient was receiving treatment for a CNS lymphoma with methotrexate and five patients had died at a median of 27 months (range 11-44 months) from symptom onset. The primary causes of death were sepsis (n = 2), systemic B cell lymphoma (n = 1), progressive neurological disease (n = 1) and uncertain (n = 1).
Proposed diagnostic criteria
Using the above clinical, radiological and pathological features, in Box 1 we propose updated diagnostic criteria, modified from prior proposed criteria (Simon et al., 2012) . For patients fulfilling all clinical, radiological and pathological criteria, we propose the term 'definite CLIPPERS'. While it is ideal that neuropathology be examined in suspected CLIPPERS, we acknowledge that, particularly given the eloquent CNS regions primarily affected, this will not be feasible in a substantial number of cases. Therefore, for patients fulfilling clinical and radiological criteria but without neuropathological examination, we propose the term 'probable CLIPPERS'. While marked corticosteroid responsiveness as well as worsening following corticosteroid withdrawal is a hallmark feature of CLIPPERS, this factor was not sufficiently discriminating to exclude a non-CLIPPERS aetiology. 
Discussion
This study defines the clinical, radiological and pathological characteristics of CLIPPERS and proposes diagnostic criteria to distinguish CLIPPERS from non-CLIPPERS aetiologies.
Patients with CLIPPERS present with subacute symptoms directly referable to the brainstem, cerebellum, cerebral white matter and spinal cord areas involved where MRI show characteristic small, punctate gadolinium enhancing lesions. Exquisite positive clinical and radiological response to corticosteroids is observed, as is reliable clinical and radiological worsening on steroid withdrawal early in the disease course. Pathologically, CLIPPERS is characterized by a marked T cell predominant lymphocytic perivascular inflammation with co-existent white and grey matter, as well as meningeal inflammation. CLIPPERS may be distinguished from non-CLIPPERS by MRI findings and when available, typical neuropathological features that also serve to definitively rule out alternative diagnoses.
We propose criteria to allow for the diagnosis of CLIPPERS, and features that, if present, suggest an alternative diagnosis. As there is currently no biomarker for CLIPPERS, a strict clinical and radiological definition is necessary to both ensure that alternative diagnoses are not overlooked and that research into the underlying aetiology is appropriately focused. The proposed features require external validation. While identifying sufficient patient numbers for external validation of the diagnostic criteria may be challenging, we encourage other centres to report on their own experiences and collaborate to increase our knowledge about CLIPPERS and other CNS diseases. A key element of these features is punctate bilateral enhancement centred on the pons and cerebellum, but which can extend into the hemispheric white matter and deep brain structures. Bilateral location of disease is an important feature pointing towards CLIPPERS as a diagnosis. Patients with unilateral enhancing lesions should be carefully evaluated for alternate causes such as neoplasms or granulomatous diseases. Response to steroids is common in these diseases, which can lead to confusion with CLIPPERS in the absence of typical radiological features. None of the biopsied patients were found to have a neoplastic process. The extent of T 2 signal abnormality tended to be similar to the extent of post-gadolinium enhancement in CLIPPERS. Areas of T 2 high signal that were much larger than the areas of post-gadolinium enhancement did not support a diagnosis of CLIPPERS.
A vascular aetiology has been proposed as an aetiology of CLIPPERS, because of reports of infarction (Saigal and Quencer, 2013) , and both small (Kleinschmidt-DeMasters and West, 2014) and large vessel abnormalities (Buttmann et al., 2013) . Widespread perivascular inflammation has been demonstrated in patients with CLIPPERS studied using pathology and 7 T MRI (Blaabjerg et al., 2016) . Vascular imaging, performed in a minority of our patients, demonstrated no significant abnormalities. Further evidence against a vasculitic aetiology in our series was the absence of features of vasculitis on brain pathology, despite prominent inflammation.
Although originally described as a predominantly T cell process, a significant plasma cell infiltration was frequently present in biopsy tissue. There were no features consistent with a glial tumour. One patient did develop a CNS lymphoma following diagnosis and treatment for CLIPPERS. This has been described previously (De Graaff et al., 2013; Alsherbini et al., 2014; Lin et al., 2014; Taieb et al., 2014) and raises the possibility that CLIPPERS represents a premalignant state. The majority of patients, however, did not develop a subsequent brain malignancy. Although multiple sclerosis has been proposed as a cause of CLIPPERS (Ortega et al., 2012; Ferreira et al., 2013) , none of the biopsied patients in this study demonstrated typical clinical, radiographic or pathological features of multiple sclerosis.
Long term treatment was successful with a variety of steroid sparing agents, suggesting that long term outcome is good in these patients if they are treated early with immunosuppressive medications. Treatment to date has consisted of unselective immunosuppressive agents, which may be appropriate, given the presence of both B and T cell populations on pathology. However, response to more agents with a more selective mode of action may allow us to determine the relative import of the presence of the T and B cell infiltrate on biopsy. Neurological decline continued in five patients, despite aggressive immunosuppression, suggesting non-inflammatory neurodegeneration also occurs in the disease.
No randomized controlled trials of treatment have been conducted in patients with CLIPPERS. Authors have reported maintenance of remission with hydroxychloroquine (Tan et al., 2015) , azathioprine (Lane et al., 2014) and even anti-tuberculous therapy (Mele et al., 2014) . Our practice has been to treat patients initially with a 5-day course of daily intravenous methyl prednisone, followed by prolonged treatment of 1 mg/kg of oral prednisone daily, with appropriate precautions regarding infection prevention, Pneumocystis pneumonia prophylaxis, osteoporosis prevention and weight management. Many patients will require chronic treatment with steroid sparing immunosuppressive therapy. Steroid sparing agents such as methotrexate or azathioprine can be started at the same time as oral prednisone and typically require doses higher than that for systemic rheumatological diseases. The optimal type and duration of therapy is uncertain given the low prevalence of the disease. A future study to evaluate comparative effectiveness of therapy strategies is needed to evaluate this. Patients who have a radiological or clinical relapse despite adequate doses of steroids should be re-evaluated for an alternate aetiology.
Time to initiation of corticosteroids was shorter in non-CLIPPERS patients than those with CLIPPERS. A possible explanation is that more of the non-CLIPPERS patients were ascertained following the original description of CLIPPERS published in 2010 and because of this knowledge of CLIPPERS as a corticosteroid-responsive syndrome, earlier trials of immunotherapy were initiated.
Limitations of this study include its retrospective nature, absence of a gold standard CLIPPERS biomarker and lack of pathology tissue in all patients. Further, the proposed diagnostic criteria may not reflect the full disease spectrum of CLIPPERS and require external validation. Attempts were made to fully ascertain data from historical records as well as contacting patients to provide updates regarding therapies, development of secondary malignancy as well as long-term outcome. While over half of the CLIPPERS cohort underwent brain biopsy despite the eloquent brain areas affected, neuropathology was not gained in all. While it is possible that pathological sampling could have missed an alternative diagnostic pathology, this is unlikely given the long follow-up without alternative diagnoses being found.
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